

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

August 2011
Volume 14, Number 8

For Health Professionals Who Care For Cancer Patients

Available online at: www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate

Inside This Issue:

- **Editor's Choice** – Highlights of Changes in Protocols, PPOs and Patient Handouts: Eligibility Clarified for Chemotherapy for Advanced NSCLC
- **Cancer Drug Manual** – Revised Monographs: Bortezomib, Carmustine, Cetuximab, Flutamide, RiTUXimab, Teniposide
- **List of New and Revised Protocols, Pre-Printed Orders and Patient Handouts** – New: HNNLAPG Revised: UCNBEV, UHNLACETRT, HNNLAPG, LUAVDC, LUAVNP, LUAVPC, LUAVPG, ULUAVPP, LUAVVIN, LUSCTOPI
- **Website Resources and Contact Information**

EDITOR'S CHOICE

HIGHLIGHTS OF CHANGES IN PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

Eligibility Clarified for Chemotherapy for Advanced NSCLC:

The **Lung Tumour Group** has clarified the eligibility of first-line chemotherapy regimens for advanced non-small cell lung cancer (NSCLC). The revised criteria include their use after patients have been first treated with an EGFR tyrosine-kinase inhibitor (e.g., Gefitinib in ULUAVGEFF).

CANCER DRUG MANUAL

REVISED MONOGRAPHS

Bortezomib Monograph has been revised to add information regarding subcutaneous administration in the Parenteral Administration table, Dosage Guidelines, and a paragraph after the Side Effects table. The intravenous dosing information in Dosage Guidelines has also been updated.

Carmustine Monograph has been revised to include historical content and references for

alternative reconstitution instructions utilizing less ethanol in the Solution Preparation and Compatibility section.

Cetuximab Monograph has been revised to include topical steroids in rash management guidelines in the paragraph after the Side Effects table.

Flutamide Monograph has been revised to modify the CYP P450 interactions in the Interactions section.

RiTUXimab Monograph has been revised to update pediatric Dosage Guidelines.

Teniposide Monograph, Patient Handout and the **Chemotherapy Preparation and Stability Chart (CPSC)** have undergone complete revisions to update all sections of the documents and to reflect current template standards. Expert review was provided by Dr. Tom Nevill (Leukemia/BMT Program) and Dr. Dawn Warkentin (VGH pharmacist, Leukemia/BMT Program).

EDITORIAL BOARD MEMBERS

The **Cancer Drug Manual Team** would like to bid farewell to CDM Editorial Board members, **Leeanne Joki** (RN) and **Dr. Anna Tinker** (Medical Oncologist, BCCA), as they step down from the board in July 2011. The team would like to thank both individuals for their many contributions to the board.

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring "Compassionate Access Program" (previously Undesignated Indications Request) approval are prefixed with the letter "U".

NEW Protocols, PPPOs and Patient Handouts (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
HNNLAPG	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Induction Treatment of Locally Advanced Nasopharyngeal Cancer with Cisplatin and Gemcitabine

REVISED PROTOCOLS, PPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPO	Patient Handout	Changes	Protocol Title
UCNBEV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dosing and Tests schedule clarified, Treatment duration and Caution for thrombosis highlighted</i>	Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab
UHNLACETRT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted</i>	Combined Cetuximab and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
HNNLAPG	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Creatinine added</i>	Induction Treatment of Locally Advanced Nasopharyngeal Cancer with Cisplatin and Gemcitabine
LUAVDC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Docetaxel
LUAVNP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Vinorelbine
LUAVPC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with CARBOplatin and PACLitaxel
LUAVPG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Platinum and Gemcitabine
ULUAVPP	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests section clarified</i>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer With Platinum and Pemetrexed
LUAVVIN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Vinorelbine in Elderly Patients
LUSCTOP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dose Modifications for renal function clarified</i>	Second-line Treatment of Recurrent Small Cell Lung Cancer (SCLC) with Topotecan

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
REIMBURSEMENT & FORMS: BENEFIT DRUG LIST, CLASS II, COMPASSIONATE ACCESS PROGRAM	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
CANCER DRUG MANUAL	www.bccancer.bc.ca/cdm
CANCER MANAGEMENT GUIDELINES	www.bccancer.bc.ca/CaMgmtGuidelines
CANCER CHEMOTHERAPY PROTOCOLS, PRE-PRINTED ORDERS, PROTOCOL PATIENT HANDOUTS	www.bccancer.bc.ca/ChemoProtocols
SYSTEMIC THERAPY PROGRAM POLICIES	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
SYSTEMIC THERAPY UPDATE	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
CON PHARMACY EDUCATORS	www.bccancer.bc.ca/RS/CommunitiesOncologyNetwork/Educators/Pharmacists

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604.877.6277		mdelemos@bccancer.bc.ca
Provincial Systemic Therapy Program	604.877.707.5973		ldasilva2@bccancer.bc.ca
Communities Oncology Network (CON)	250.519.5501		jdenduyf@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 2638		nursinged@bccancer.bc.ca
Library/Cancer Information	888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 2623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Mário de Lemos, PharmD, MSc (Oncol) (Editor)
 Johanna Den Duyf, MA
 Judy Oliver, BScN, MEd
 Beth Morrison, MLS

Caroline Lohrisch, MD
 Sally Man, PharmD (Assistant Editor)
 Jaya Venkatesh, MHA, CMA
 Susan Walisser, BSc (Pharm)